Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Share-based Compensation (2017 - 2020)

Monopar Therapeutics (MNPR) has disclosed Share-based Compensation for 4 consecutive years, with $331322.0 as the latest value for Q4 2020.

  • Quarterly Share-based Compensation rose 19.7% to $331322.0 in Q4 2020 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Dec 2020, up 30.63% year-over-year, with the annual reading at $1.1 million for FY2024, 39.89% down from the prior year.
  • Share-based Compensation hit $331322.0 in Q4 2020 for Monopar Therapeutics, up from $283713.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $367358.0 in Q2 2020 to a low of $3612.0 in Q3 2017.
  • Historically, Share-based Compensation has averaged $209156.6 across 4 years, with a median of $238366.0 in 2019.
  • Biggest five-year swings in Share-based Compensation: soared 2481.51% in 2018 and later grew 16.78% in 2020.
  • Year by year, Share-based Compensation stood at $63189.0 in 2017, then soared by 268.72% to $232992.0 in 2018, then increased by 18.8% to $276805.0 in 2019, then rose by 19.7% to $331322.0 in 2020.
  • Business Quant data shows Share-based Compensation for MNPR at $331322.0 in Q4 2020, $283713.0 in Q3 2020, and $367358.0 in Q2 2020.